DR. ASHER D SCHACHTER, M.D.
Medical Practice at Longwood Ave, Boston, MA

License number
Massachusetts 153413
Category
Medical Practice
Type
Pediatrics
License number
Massachusetts 153413
Category
Medical Practice
Type
Pediatric Nephrology
Address
Address 2
300 Longwood Ave, Boston, MA 02115
17 Plymouth Rd, Needham, MA 02492
Phone
(617) 355-6129
(617) 730-0569 (Fax)
(781) 449-4404

Personal information

See more information about ASHER D SCHACHTER at radaris.com
Name
Address
Phone
Asher Schachter, age 57
17 Plymouth Rd, Needham, MA 02492
(617) 417-9792
Asher Schachter
Needham, MA
(781) 449-4710
Asher D Schachter, age 57
17 Plymouth Rd, Needham, MA 02492
(781) 449-4710
Asher D Schachter, age 57
234 Corey Rd, Brighton, MA 02135
Asher Schachter
1443 Beacon St, Brookline, MA 02446
(617) 738-5060

Professional information

See more information about ASHER D SCHACHTER at trustoria.com
Asher Schachter Photo 1
Translational Medicine, New Indications Discovery Unit (Nidu), Novartis Institutes For Biomedical Research (Nibr)

Translational Medicine, New Indications Discovery Unit (Nidu), Novartis Institutes For Biomedical Research (Nibr)

Position:
Translational Medicine Expert (TME)/Senior Investigator II, New Indications Discovery Unit at Novartis, Founder, Webmaster at kt-v.net
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
Novartis since Jan 2011 - Translational Medicine Expert (TME)/Senior Investigator II, New Indications Discovery Unit kt-v.net since 2002 - Founder, Webmaster
Education:
Harvard-MIT Division of Health Sciences & Technology (HST) 2001 - 2003
MS, Biomedical Informatics
Harvard-MIT Division of Health Sciences & Technology (HST) 1999 - 2001
MMSc, Clinical Investigation
University of Toronto 1988 - 1992
MD, Medicine
Skills:
Informatics, Data Mining, Translational Medicine, Pediatric Nephrology, Data Visualization, Proof-of-concept (PoC) clinical trials, technical computing in R, Nephrology, Pediatrics, Drug Development, Clinical Research, Clinical Development, Biomarker Discovery, Clinical Trials, Medical Research


Asher D Schachter Photo 2
Dr. Asher D Schachter - MD (Doctor of Medicine)

Dr. Asher D Schachter - MD (Doctor of Medicine)

Hospitals:
300 Longwood Ave, Boston 02115
UMass Memorial Medical Center - University Campus
55 Lake Ave North, Worcester 01655
300 Longwood Ave, Boston 02115
UMass Memorial Medical Center - University Campus
55 Lake Ave North, Worcester 01655
Education:
Medical Schools
University Of Toronto Faculty Of Medicine
Graduated: 1992


Asher Daniel Schachter Photo 3
Asher Daniel Schachter, Boston MA

Asher Daniel Schachter, Boston MA

Specialties:
Pediatrics, Pediatric Nephrology, Nephrology
Work:
Children's Hospital
300 Longwood Ave, Boston, MA 02115
Education:
University Of Toronto Faculty Of Medicine (1992)


Asher Schachter Photo 4
Predicting Graft Rejection

Predicting Graft Rejection

US Patent:
2007012, May 31, 2007
Filed:
Feb 17, 2004
Appl. No.:
10/545198
Inventors:
Terry Strom - Brookline MA, US
Towia Libermann - Chestnut Hill MA, US
Asher Schachter - Needham MA, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention features prognostic methods useful in assessing patients who have received a transplant and reagents, optionally packaged as kits or organized as arrays, that can be used to carry out those methods. The inventions are based, in part, on our analysis of gene expression in renal allografts and clinical parameters, such as the age of the donor. The clinical parameters include one or more variables associated with the recipient (e.g., the recipient's age and/or race); one or more variables associated with the graft (e.g., whether the graft is obtained from a living donor or a cadaver and the ischemic time); and variables associated with the donor (e.g., the donor's age and/or race). The genes that can be assessed include those encoding agents that mediate inflammation, immune activation, and cell death (we may refer to these genes below as “inflammatory”, “immune” or “cytoprotective”). Surprisingly, we found that the levels of gene expression could predict the occurrence of DGF, AR, and the quality of later graft function even when analyzed shortly after the transplant was performed (e.g., shortly after vascular anastomosis and tissue reperfusion). We also found that clinical parameters available at the time of transplantation correlate with decreased graft health and can be considered in combination with gene expression to evaluate a patient's risk for an adverse outcome.


Asher Schachter Photo 5
Method And Apparatus For Evaluating New Chemical Entities

Method And Apparatus For Evaluating New Chemical Entities

US Patent:
2005002, Jan 27, 2005
Filed:
Jun 30, 2004
Appl. No.:
10/881322
Inventors:
Asher Schachter - Needham MA, US
Marco Ramoni - Boston MA, US
International Classification:
G01N033/50
US Classification:
702019000
Abstract:
A method for predicting the success of a new chemical entity, including the steps of providing a signal related to the new chemical entity, providing a therapeutic index, providing a conditional probability table, providing a prior probability distribution, providing a prior N, and calculating a posterior probability distribution for the new chemical entity. An apparatus for predicting the success of a new chemical entity including an input for a signal related to the new chemical entity, a therapeutic index, a conditional probability table, a prior probability distribution, a prior N, and a processor calculating a posterior probability distribution for the new chemical entity.